8 January 2026 -- Perth, Australia | BlinkLab Limited (ASX:BB1) (“BlinkLab” or the “Company”) has announced that it has received $822,205 under the Australian Government’s Research and Development (R&D) Tax Incentive program.
The refund relates to eligible R&D expenditure incurred in connection with BlinkLab’s U.S. pilot study and its clinical research initiatives conducted in Australia, including collaborative research undertaken with the MAGNET study at Monash University.
These Australian and overseas activities support the development, validation and clinical investigation of the Company’s smartphone-based neurobehavioural assessment technology in autism. Funds received from the R&D Tax Incentive will be applied to support BlinkLab’s ongoing research and development activities, including continued clinical studies and broader product and regulatory development programs.
Receipt of the refund provides additional financial flexibility as the Company prepares to initiate its main FDA study and commence participant enrolment.
About us:
About BlinkLab Limited (ASX:BB1)
BlinkLab Limited is a company founded by neuroscientists at Princeton University and has developed a smartphone-based diagnostic platform for autism and ADHD. Its most advanced product is an autism diagnostic aid for clinicians that leverages smartphones, artificial intelligence and machine learning to support early and accurate detection of autism, enabling early intervention during critical periods of brain development. BlinkLab is led by an experienced management team and Board with deep expertise in digital healthcare, computer vision, AI and machine learning, supported by a Scientific Advisory Board of leading experts in autism and brain development.
Contact details:
Jane Morgan
Jane Morgan Management
Investor & Media Relations
[email protected]
